DOI QR코드

DOI QR Code

Nrf2 Overexpression Predicts Prognosis and 5-FU Resistance in Gastric Cancer

  • Hu, Xiu-Feng (Department of Oncology, Cancer Research Institute, the First Affiliated Hospital of Henan University of Science and Technology) ;
  • Yao, Jun (Department of Oncology, Cancer Research Institute, the First Affiliated Hospital of Henan University of Science and Technology) ;
  • Gao, She-Gan (Department of Oncology, Cancer Research Institute, the First Affiliated Hospital of Henan University of Science and Technology) ;
  • Wang, Xin-Shuai (Department of Oncology, Cancer Research Institute, the First Affiliated Hospital of Henan University of Science and Technology) ;
  • Peng, Xiu-Qing (Department of Oncology, Cancer Research Institute, the First Affiliated Hospital of Henan University of Science and Technology) ;
  • Yang, Yan-Tong (Department of Oncology, Cancer Research Institute, the First Affiliated Hospital of Henan University of Science and Technology) ;
  • Feng, Xiao-Shan (Department of Oncology, Cancer Research Institute, the First Affiliated Hospital of Henan University of Science and Technology)
  • Published : 2013.09.30

Abstract

Objective: NF-E2-related factor 2 (Nrf2) is activated in several human malignancies. However, the role of Nrf2 in gastric cancer (GC) remains incompletely understood. In this study, we therefore analyzed associations of Nrf2 expression status with clinical features and chemotherapeutic resistance in GC. Materials and Methods: A total of 186 samples from GC patients who underwent gastrectomy were used for prognostic assessment. A further 142 samples from GC cases who received first-line combination chemotherapy were applied for investigation of chemoresistance. The Nrf2 expression was evaluated by immunohistochemistry in GC samples, and its relationship with clinicopathological parameters and chemotherapy sensitivity was analyzed. The effect of Nrf2 gene silencing on chemotherapy resistance was also examined by cell viability assay in vivo. Results: Of the 186 patients with GC, 104/186 (55.9%) showed high expression for Nrf2. The overexpression of Nrf2 was an independent predictor of overall survival [OS, hazard ratio (HR) 3.9; P=0.011] and disease-free survival (DFS, HR 4.3; P=0.002). The gene silencing of Nrf2 reduced resistance to cell death induced by 5-FU in GC cell lines. Conclusion: Our data show that Nrf2 is an independent prognostic factor in GC. Furthermore, Nrf2 confers resistance to chemotherapeutic drug 5-FU in GC cells. Taken together, Nrf2 is a potential prognostic marker and predictive for 5-FU resistance in GC.

Keywords

Gastric cancer;Nrf2;drug resistance;prognosis

References

  1. Ajani JA, Moiseyenko VM, Tjulandin S, et al (2007). Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol, 25, 3205-9. https://doi.org/10.1200/JCO.2006.10.4968
  2. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  3. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD (2008). Dual roles of Nrf2 in cancer. Pharmacol Res, 58, 262-70. https://doi.org/10.1016/j.phrs.2008.09.003
  4. Huang JY, Xu YY, Sun Z, et al (2012). Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 13, 4379-85. https://doi.org/10.7314/APJCP.2012.13.9.4379
  5. Inoue D, Suzuki T, Mitsuishi Y, et al (2012). Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci, 103, 760-6. https://doi.org/10.1111/j.1349-7006.2012.02216.x
  6. Jala VR, Radde BN, Haribabu B, Klinge CM (2012). Enhanced expression of G-protein coupled estrogen receptor (GPER/ GPR30) in lung cancer. BMC Cancer, 12, 624. https://doi.org/10.1186/1471-2407-12-624
  7. Ma X, Zhang J, Liu S, et al (2012). Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer. Cancer Chemother Pharmacol, 69, 485-94. https://doi.org/10.1007/s00280-011-1722-9
  8. Merikallio H, Pääkkö P, Kinnula VL, Harju T, Soini Y (2012). Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol, 43, 577-84. https://doi.org/10.1016/j.humpath.2011.05.024
  9. Shelton P, Jaiswal AK (2013). The transcription factor NF-E2- related factor 2 (Nrf2): a protooncogene? FASEB J, 27, 414-23. https://doi.org/10.1096/fj.12-217257
  10. Shibata T, Kokubu A, Saito S, et al (2011). NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia, 13, 864-73. https://doi.org/10.1593/neo.11750
  11. Singh A, Bodas M, Wakabayashi N, Bunz F, Biswal S (2010). Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signal, 13, 1627-37. https://doi.org/10.1089/ars.2010.3219
  12. Solis LM, Behrens C, Dong W, et al (2010). Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res, 6, 3743-53.
  13. Yamamoto K, Fujiwara Y, Nishida T, et al (2009). Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer. Anticancer Res, 29, 4211-5.
  14. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
  15. Wagner AD, GrotheW, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: a systematic review and metaanalysis based on aggregate data. J Clin Oncol, 24, 2903-9. https://doi.org/10.1200/JCO.2005.05.0245
  16. Wang XJ, Sun Z, Villeneuve NF, et al (2008). Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis, 29, 1235-43. https://doi.org/10.1093/carcin/bgn095
  17. Yang H, Wang W, Zhang Y, et al (2011). The role of NF-E2- related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer. Clin Lung Cancer, 12, 166-71. https://doi.org/10.1016/j.cllc.2011.03.012
  18. Yoichiro Mitsuishi, Hozumi Motohashi, Masayuki Yamamoto (2012). The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol, 2, 200.
  19. Zhang DD (2010). The Nrf2-Keap1-ARE signaling pathway: The regulation and dual function of Nrf2 in cancer. Antioxid Redox Signal, 13, 1623-6. https://doi.org/10.1089/ars.2010.3301
  20. Zhang P, Singh A, Yegnasubramanian S, et al (2010). Loss of Kelch-like ECH- associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther, 9, 336-46. https://doi.org/10.1158/1535-7163.MCT-09-0589

Cited by

  1. Experimental Study on Sustained-release 5-Fluorouracil Implantation in Canine Peritoneum and Para-aortic Abdominalis vol.15, pp.1, 2014, https://doi.org/10.7314/APJCP.2014.15.1.407
  2. Luteolin-loaded Phytosomes Sensitize Human Breast Carcinoma MDA-MB 231 Cells to Doxorubicin by Suppressing Nrf2 Mediated Signalling vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5311
  3. Luteolin Sensitizes Two Oxaliplatin-Resistant Colorectal Cancer Cell Lines to Chemotherapeutic Drugs Via Inhibition of the Nrf2 Pathway vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2911
  4. Targeting the NF-E2-related factor 2 pathway: A novel strategy for glioblastoma (Review) vol.32, pp.2, 2014, https://doi.org/10.3892/or.2014.3259
  5. Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer vol.13, pp.1, 2015, https://doi.org/10.1186/s12957-015-0737-9
  6. Sodium Selenite Inhibits Proliferation of Gastric Cancer Cells by Inducing SBP1 Expression vol.239, pp.4, 2016, https://doi.org/10.1620/tjem.239.279
  7. Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents vol.37, pp.8, 2016, https://doi.org/10.1007/s13277-016-5015-0
  8. Mitochondria, cholesterol and cancer cell metabolism vol.5, pp.1, 2016, https://doi.org/10.1186/s40169-016-0106-5
  9. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2 vol.12, pp.5, 2017, https://doi.org/10.1371/journal.pone.0177227
  10. Overexpression of NRF2 is correlated with prognoses of patients with malignancies: A meta-analysis vol.8, pp.6, 2017, https://doi.org/10.1111/1759-7714.12462
  11. Camptothecin suppresses NRF2–ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs pp.1532-1827, 2017, https://doi.org/10.1038/bjc.2017.317
  12. Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways vol.2018, pp.1942-0994, 2018, https://doi.org/10.1155/2018/9482018
  13. UVA Irradiation Enhances Brusatol-Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2-Mediated Antioxidant Response vol.2018, pp.1942-0994, 2018, https://doi.org/10.1155/2018/9742154
  14. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma vol.19, pp.11, 2018, https://doi.org/10.3390/ijms19113503
  15. A catalogue of somatic NRF2 gain-of-function mutations in cancer vol.8, pp.1, 2018, https://doi.org/10.1038/s41598-018-31281-0
  16. vol.52, pp.6, 2018, https://doi.org/10.1080/10715762.2018.1462494
  17. NRF2 addiction in cancer cells vol.109, pp.4, 2018, https://doi.org/10.1111/cas.13537
  18. Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer vol.15, pp.1, 2015, https://doi.org/10.1186/s12885-015-1008-4
  19. Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes vol.41, pp.1, 2019, https://doi.org/10.1177/1010428318815413